Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.

@article{Storch2013DoubleblindPP,
  title={Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.},
  author={Eric A. Storch and Andrew W. Goddard and Jon E Grant and Alessandro S. De Nadai and Wayne K. Goodman and P. Jane Mutch and Carla E Medlock and Brian Lawrence Odlaug and Christopher J. McDougle and Tanya K. Murphy},
  journal={The Journal of clinical psychiatry},
  year={2013},
  volume={74 6},
  pages={e527-32}
}
OBJECTIVE This pilot study explored the efficacy and tolerability of paliperidone augmentation of serotonin reuptake inhibitors (SRIs) in adults with treatment-resistant obsessive-compulsive disorder (OCD). METHOD Thirty-four patients aged 24-67 years (mean = 43.7 years, SD = 11.4) who met DSM-IV criteria for OCD and remained symptomatic following 2 or more past adequate SRI trials (including their current medication) were enrolled from May 2008 to March 2012. Participants were treated for 8… CONTINUE READING